NASDAQ:RUBY
Delisted
Rubius Therapeutics Inc. Stock News
$0.0570
+0 (+0%)
At Close: Mar 28, 2024
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an en
Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
08:00am, Thursday, 18'th Feb 2021
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an en
Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days
04:45pm, Wednesday, 03'rd Feb 2021
CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an en
Rubius: Watson, We Have No Data
03:39am, Tuesday, 26'th Jan 2021
Rubius has an interesting science hypothesis, however it failed a first proof of concept trial. It is now running its next one. They have adequate cash for the time being.
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
04:01pm, Monday, 04'th Jan 2021
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an en
Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference
04:00pm, Monday, 30'th Nov 2020
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
04:01pm, Tuesday, 10'th Nov 2020
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent
Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline
08:05am, Monday, 09'th Nov 2020
Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2 Solid Tumor Clinical Trial
RTX-240 Demonstrates Promotion of T Cell and Natural Killer Cell Activation and Expansion In Vitro and In Vivo RTX-240 Demonstrates Promotion of T Cell and Natural Killer Cell Activation and Expansion
Rubius Therapeutics to Announce Third Quarter 2020 Financial Results
04:30pm, Thursday, 29'th Oct 2020
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an en
RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Innate and Adaptive Immune Responses RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Inn
